CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 128 filers reported holding CYTOMX THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.74 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $75,953 | +37.3% | 50,300 | +45.5% | 0.00% | – |
Q4 2022 | $55,320 | +53.7% | 34,575 | +36.0% | 0.00% | – |
Q3 2022 | $36,000 | -47.1% | 25,430 | -32.2% | 0.00% | – |
Q2 2022 | $68,000 | -80.8% | 37,501 | -18.5% | 0.00% | -100.0% |
Q1 2021 | $355,000 | -79.7% | 45,988 | -82.8% | 0.00% | -75.0% |
Q4 2020 | $1,749,000 | +18.6% | 266,986 | +20.4% | 0.01% | +33.3% |
Q3 2020 | $1,475,000 | -8.9% | 221,812 | +14.1% | 0.01% | -25.0% |
Q2 2020 | $1,619,000 | -22.5% | 194,412 | -28.6% | 0.01% | -42.9% |
Q1 2020 | $2,089,000 | -21.6% | 272,410 | -15.0% | 0.01% | +55.6% |
Q4 2019 | $2,665,000 | +3406.6% | 320,655 | +2999.3% | 0.01% | – |
Q3 2019 | $76,000 | -91.4% | 10,346 | -87.4% | 0.00% | -100.0% |
Q1 2019 | $879,000 | -57.6% | 81,798 | -40.4% | 0.00% | -66.7% |
Q4 2018 | $2,073,000 | -36.4% | 137,261 | -22.1% | 0.01% | -25.0% |
Q3 2018 | $3,259,000 | -60.6% | 176,160 | -51.3% | 0.01% | -64.7% |
Q2 2018 | $8,270,000 | -28.7% | 361,750 | -11.2% | 0.03% | -35.8% |
Q1 2018 | $11,593,000 | – | 407,483 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |